{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T02:40:43Z","timestamp":1699756843431},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00404-021-06308-z","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T15:02:26Z","timestamp":1635778946000},"page":"1311-1318","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer"],"prefix":"10.1007","volume":"305","author":[{"given":"Mahtab","family":"Yazdian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Groeben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais","family":"Baert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareike","family":"Bommert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Traut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Elfers-Wassenhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Br\u00fc\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Schwameis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"6308_CR1","unstructured":"S3-Leitlinie (2019) Maligne ovarialtumoren, Ovarialkarzinom, p 79"},{"key":"6308_CR2","first-page":"369","volume":"55","author":"JA Nagy","year":"1995","unstructured":"Nagy JA, Masse E, Herzberg K et al (1995) Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 55:369\u2013375","journal-title":"Cancer Res"},{"key":"6308_CR3","doi-asserted-by":"crossref","unstructured":"Dvorak HF (1986) Tumors: wounds that do not heal Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650\u20131659","DOI":"10.1056\/NEJM198612253152606"},{"key":"6308_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1479-5876-3-25","volume":"3","author":"X Wang","year":"2005","unstructured":"Wang X, Wang E, Kavanagh J et al (2005) Ovarian cancer, the coagulation pathway and inflammation. J Transl Med 3:25","journal-title":"J Transl Med"},{"key":"6308_CR5","first-page":"219","volume":"130","author":"DY Shi","year":"2017","unstructured":"Shi DY, Wang SJ (2017) Advances of coagulation factor XIII. Chin Med J 130:219\u2013223","journal-title":"Chin Med J"},{"issue":"1","key":"6308_CR6","first-page":"11","volume":"22","author":"GS Dufner","year":"2002","unstructured":"Dufner GS, Marbet GA (2002) Factor XIII in man: a review. Hamostaseologie 22(1):11\u201319","journal-title":"Hamostaseologie"},{"key":"6308_CR7","doi-asserted-by":"publisher","first-page":"e0128113","DOI":"10.1371\/journal.pone.0128113","volume":"10","author":"C Andersson","year":"2015","unstructured":"Andersson C, Kvist P, McEllhiney K et al (2015) Factor XIII transglutaminase supports the resolution of mucosal damage in experimental colitis. PLoS ONE 10:e0128113","journal-title":"PLoS ONE"},{"key":"6308_CR8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1160\/TH05-04-0291","volume":"94","author":"A Inbal","year":"2005","unstructured":"Inbal A, Lubetsky A, Krapp T et al (2005) Impaired wound healing in factor XIII deficient mice. Thromb Haemost 94:432\u2013437","journal-title":"Thromb Haemost"},{"key":"6308_CR9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1440-1746.2006.04319.x","volume":"21","author":"S Higaki","year":"2006","unstructured":"Higaki S, Nakano K, Onaka S et al (2006) Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn\u2019s disease. J Gastroenterol Hepatol 21:1407\u20131411","journal-title":"J Gastroenterol Hepatol"},{"key":"6308_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1538-7836.2008.02938.x","volume":"6","author":"JS Palumbo","year":"2008","unstructured":"Palumbo JS, Barney KA, Blevins EA et al (2008) Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 6:812\u2013819","journal-title":"J Thromb Haemost"},{"key":"6308_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-4939-7196-1_22","volume":"1646","author":"L Muszbek","year":"2017","unstructured":"Muszbek L, Katona \u00c9, Ker\u00e9nyi A (2017) Assessment of factor XIII. Methods Mol Biol 1646:277\u2013293","journal-title":"Methods Mol Biol"},{"issue":"1","key":"6308_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-0038-1676580","volume":"45","author":"A Dorgalaleh","year":"2019","unstructured":"Dorgalaleh A, Tabibian S, Shams M et al (2019) A unique factor XIII mutation in southeastern iran with an unexpectedly high prevalence: khash factor XIII. Semin Thromb Hemost 45(1):43\u201349","journal-title":"Semin Thromb Hemost"},{"key":"6308_CR13","doi-asserted-by":"crossref","unstructured":"Ichinose A (2017) Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII\/13 antibodies: A summary of 93 patients. Blood Rev 31(1):37\u201345","DOI":"10.1016\/j.blre.2016.08.002"},{"key":"6308_CR14","doi-asserted-by":"publisher","DOI":"10.1055\/b-002-19466","volume-title":"Gerinnungskonsil","author":"B P\u00f6tzsch","year":"2002","unstructured":"P\u00f6tzsch B, Madlener K (2002) Gerinnungskonsil. Thieme Verlag, Rationelle Diagnostik und Therapie von Gerinnungsst\u00f6rungen. Stuttgart"},{"issue":"2","key":"6308_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213","journal-title":"Ann Surg"},{"issue":"6","key":"6308_CR16","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3349\/ymj.2013.54.6.1394","volume":"54","author":"SH Lee","year":"2013","unstructured":"Lee SH, Suh IB, Lee EJ et al (2013) Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer. Yonsei Med J 54(6):1394\u20131399","journal-title":"Yonsei Med J"},{"key":"6308_CR17","doi-asserted-by":"crossref","unstructured":"Kappelmayer J, Simon A, Katona E et al (2005) Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias. Thromb Haemost 94(2):454\u20139.","DOI":"10.1160\/TH05-03-0206"},{"key":"6308_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380:822\u2013832","journal-title":"N Engl J Med"},{"issue":"9990","key":"6308_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249\u2013257","journal-title":"Lancet"},{"issue":"12","key":"6308_CR20","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1245\/s10434-017-6079-9","volume":"24","author":"A Kahl","year":"2017","unstructured":"Kahl A, du Bois A, Harter P et al (2017) Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer. Ann Surg Oncol 24(12):3692\u20133699","journal-title":"Ann Surg Oncol"},{"key":"6308_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1006\/gyno.2001.6353","volume":"83","author":"A Obermair","year":"2001","unstructured":"Obermair A, Hagenauer S, Tamandl D et al (2001) Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83:115\u2013120","journal-title":"Gynecol Oncol"},{"issue":"3","key":"6308_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2015.07.005","volume":"138","author":"B Ataseven","year":"2015","unstructured":"Ataseven B, du Bois A, Reinthaller A et al (2015) Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol 138(3):560\u2013565","journal-title":"Gynecol Oncol"},{"issue":"2","key":"6308_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ygyno.2008.03.008","volume":"110","author":"KN Moore","year":"2008","unstructured":"Moore KN, Reid NS, Fong DN et al (2008) Ovarian cancer in octogenarian: does the paradigm of cytoreductive surgery and chemotherapy still apply? Gynecol Oncol 110(2):133\u2013139","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6308_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","volume":"120","author":"GD Aletti","year":"2011","unstructured":"Aletti GD, Eisenhauer EL, Santillan A et al (2011) Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 120(1):23\u201328","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6308_CR25","first-page":"63","volume":"37","author":"GM Nieuwenhuyzen-de Boer","year":"2016","unstructured":"Nieuwenhuyzen-de Boer GM, Gerestein CG, Eijkemans MJ, Burger CW, Kooi GS (2016) Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Gynaecol Oncol 37(1):63\u201368","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"6308_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2017.06.007","volume":"146","author":"C Grimm","year":"2017","unstructured":"Grimm C, Harter P, Alesina PF et al (2017) The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol 146(3):498\u2013503","journal-title":"Gynecol Oncol"},{"issue":"5","key":"6308_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248\u20131259","journal-title":"J Clin Oncol"},{"key":"6308_CR28","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"15","author":"A Du Bois","year":"2009","unstructured":"Du Bois A, Reuss A, Pujade-Lauraine E et al (2009) The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. Cancer 15:1234\u20131244","journal-title":"Cancer"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-021-06308-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T02:22:08Z","timestamp":1699755728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-021-06308-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6308"],"URL":"https:\/\/doi.org\/10.1007\/s00404-021-06308-z","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"5 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest regarding the submitted work. Dr. Ataseven reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees from Astra Zeneca, personal fees and non-financial support from Tesaro\/GSK, personal fees from Clovis, personal fees from Celgene, non-financial support from PharmaMar, outside the submitted work. Prof. du Bois reports personal fees and non-financial support from Roche, Astra Zeneca, Tesaro\/GSK, Clovis, BIOCAD, non-financial support from Pfizer, Genmab\/Seattle Genetics and MSD, outside the submitted work. Dr. Harter reports grants and personal fees from Astra Zeneca, grants and personal fees from Roche, personal fees from Sotio, grants and personal fees from Tesaro, personal fees from Stryker, personal fees from Zai Lab, personal fees from MSD, grants and personal fees from Public funding (ASCO, DKH, DFG), personal fees from Clovis, personal fees from Immunogen, grants and personal fees from GSK, grants from Boehringer Ingelheim, grants from Medac, grants from Genmab, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}